Development of the lichen planus quality of life questionnaire (LPQoL) informed by expert clinician input and patient feedback: a retrospective survey study.

Lichen planopilaris Lichen planus Mucosal disease Patient-reported outcome measures Quality of life

Journal

Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 11 07 2022
accepted: 11 01 2023
revised: 09 01 2023
medline: 14 7 2023
pubmed: 31 1 2023
entrez: 30 1 2023
Statut: ppublish

Résumé

Lichen planus (LP) can affect multiple body sites including skin, mucosae, scalp and nails, causing considerable impact on patients' quality of life. Currently, there are no LP patient-reported outcome measures (PROMs) that address all body sites potentially affected by LP. We developed a LP Quality of Life Questionnaire (LPQoL), informed by an expert consortium and patient survey study, to address this gap. The study was approved by our institution's Institutional Review Board. First, a 22-item LPQoL was designed with input from LP experts at our institution. The tool was then optimized by garnering input from patients recently diagnosed with LP, who were asked to complete the LPQoL, as well as the Dermatology Life Quality Index (DLQI) and a feedback form about the LPQoL. Fifty-eight of 150 patients (39% response rate) returned the questionnaire. Mean DLQI score was 4.9 ± 5.6 SD (range 0-25) and mean LPQoL score was 13.6 ± 10.4 SD (range 0-54). LPQoL score was positively correlated with DLQI score (r = 0.79; p < 0.001). Forty-nine out of 56 (88%) and 6/56 (11%) rated the LPQoL as 'very easy' or 'fairly easy' to complete, respectively. Based on participants' feedback, we increased the recall period from one week to one month and added questions on esophageal involvement. With iterative input from LP experts and patients, we developed a LPQoL to address the gap in a multi-site PROM specific to LP. This is a pilot study and there is ongoing validation studies; therefore, this measure should not be used in clinical practice or research until validated.

Identifiants

pubmed: 36715723
doi: 10.1007/s00403-023-02534-4
pii: 10.1007/s00403-023-02534-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1561-1569

Subventions

Organisme : British Association of Dermatologists
ID : Geoffrey Dowling Fellowship

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Lehman JS, Tollefson MM, Gibson LE (2009) Lichen planus. Int J Dermatol 48(7):682–694
doi: 10.1111/j.1365-4632.2009.04062.x pubmed: 19570072
Fahy CMR, Torgerson RR, Davis MDP (2017) Lichen planus affecting the female genitalia: a retrospective review of patients at Mayo Clinic. J Am Acad Dermatol 77(6):1053–1059
doi: 10.1016/j.jaad.2017.07.030 pubmed: 29031660
Fiocco Z, Kupf S, Patzak L, Kämmerer T, Pumnea T, French LE et al (2021) Quality of life and psychopathology in lichen planus: a neglected disease burden. Acta Derm Venereol 101(12):adv00619
doi: 10.2340/actadv.v101.442 pubmed: 34698356
Wiriyakijja P, Porter S, Fedele S, Hodgson T, McMillan R, Shephard M et al (2020) Meaningful improvement thresholds in measures of pain and quality of life in oral lichen planus. Oral Dis 26(7):1464–1473
doi: 10.1111/odi.13379 pubmed: 32363637
Wiriyakijja P, Porter S, Fedele S, Hodgson T, McMillan R, Shephard M et al (2020) Health-related quality of life and its associated predictors in patients with oral lichen planus: a cross-sectional study. Int Dent J. https://doi.org/10.1111/idj.12607
doi: 10.1111/idj.12607 pubmed: 32875594
Yuwanati M, Gondivkar S, Sarode SC, Gadbail A, Sarode GS, Patil S et al (2021) Impact of oral lichen planus on oral health-related quality of life: a systematic review and meta-analysis. Clin Pract 11(2):272–286
doi: 10.3390/clinpract11020040 pubmed: 34067014 pmcid: 8161446
Slade GD (1997) Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol 25(4):284–290
doi: 10.1111/j.1600-0528.1997.tb00941.x pubmed: 9332805
Wiriyakijja P, Porter S, Fedele S, Hodgson T, McMillan R, Shephard M et al (2020) Development and validation of a short version of Chronic Oral Mucosal Disease Questionnaire (COMDQ-15). J Oral Pathol Med 49(1):55–62
doi: 10.1111/jop.12964 pubmed: 31605549
Ni Riordain R, Meaney S, McCreary C (2011) A patient-centered approach to developing a quality-of-life questionnaire for chronic oral mucosal diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111(5):578–86, 86.e1-2
doi: 10.1016/j.tripleo.2010.12.011 pubmed: 21429772
Lorenzo-Pouso AI, Rodríguez-González F, Blanco-Carrión A, García-García A, Chamorro-Petronacci C, López-Jornet P et al (2020) Validity, reliability and optimisation of the TOPICOP questionnaire for oral lichen planus. Acta Odontol Scand 78(7):501–508
doi: 10.1080/00016357.2020.1739329 pubmed: 32189543
Sadownik LA, Koert E, Maher C, Smith KB (2020) A qualitative exploration of women’s experiences of living with chronic vulvar dermatoses. J Sex Med 17(9):1740–1750
doi: 10.1016/j.jsxm.2020.06.016 pubmed: 32741746
Cheng H, Oakley A, Conaglen JV, Conaglen HM (2017) Quality of life and sexual distress in women with erosive vulvovaginal lichen planus. J Low Genit Tract Dis 21(2):145–149
doi: 10.1097/LGT.0000000000000282 pubmed: 27906807
Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216
doi: 10.1111/j.1365-2230.1994.tb01167.x pubmed: 8033378
Lewis V, Finlay AY (2004) 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 9(2):169–180
doi: 10.1111/j.1087-0024.2004.09113.x pubmed: 15083785
Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY (2015) Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 230(1):27–33
doi: 10.1159/000365390 pubmed: 25613671
Chren MM (2012) The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 30(2):231–6, xiii
doi: 10.1016/j.det.2011.11.003 pubmed: 22284137
Chren MM, Lasek RJ, Sahay AP, Sands LP (2001) Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 5(2):105–110
doi: 10.1177/120347540100500202 pubmed: 11443481
Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ (1997) Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 133(11):1433–1440
doi: 10.1001/archderm.1997.03890470111018 pubmed: 9371029
Morgan M, McCreedy R, Simpson J, Hay RJ (1997) Dermatology quality of life scales–a measure of the impact of skin diseases. Br J Dermatol 136(2):202–206
pubmed: 9068732
Zeidler C, Steinke S, Riepe C, Bruland P, Soto-Rey I, Storck M et al (2019) Cross-European validation of the ItchyQoL in pruritic dermatoses. J Eur Acad Dermatol Venereol 33(2):391–397
doi: 10.1111/jdv.15225 pubmed: 30193410
Kirby JS, Thorlacius L, Villumsen B, Ingram JR, Garg A, Christensen KB et al (2020) The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol 183(2):340–348
doi: 10.1111/bjd.18692 pubmed: 31705538
Gabes M, Jourdan C, Schramm K, Masur C, Abels C, Kamudoni P et al (2021) Hyperhidrosis Quality of Life Index (HidroQoL(c)): further validation and clinical application in patients with axillary hyperhidrosis using data from a phase III randomized controlled trial. Br J Dermatol 184(3):473–481
doi: 10.1111/bjd.19300 pubmed: 32510573
Tjokrowidjaja A, Daniel BS, Frew JW, Sebaratnam DF, Hanna AM, Chee S et al (2013) The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease. Br J Dermatol 169(5):1000–1006
doi: 10.1111/bjd.12623 pubmed: 24102329
Ogunsanya ME, Cho SK, Hudson A, Chong BF (2019) Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus. Br J Dermatol 180(6):1430–1437
doi: 10.1111/bjd.17636 pubmed: 30637718 pmcid: 6546517
Morken CM, Bhullar PK, Boudreaux BW, Xie F, Zhang N, Lehman JS, Pittelkow MR, Mangold AR (2022) Availability of a validated cutaneous lichen planus disease index: a systematic review. Int J Dermatol. https://doi.org/10.1111/ijd.16563 PMID: 36529946
doi: 10.1111/ijd.16563 pubmed: 36529946
Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY (2008) The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol 159(5):997–1035
pubmed: 18795920
Beavers AS, Lounsbury JW, Richards JK, Huck SW, Skolits GJ, Esquivel SL (2013) Practical considerations for using exploratory factor analysis in educational research. Practical Assess Res Eval 18:6
Finlay AY (1997) Quality of life measurement in dermatology: a practical guide. Br J Dermatol 136(3):305–314
doi: 10.1046/j.1365-2133.1997.5541510.x pubmed: 9115906
Finlay AY, Salek MS, Abeni D, Tomas-Aragones L, van Cranenburgh OD, Evers AW et al (2017) Why quality of life measurement is important in dermatology clinical practice: An expert-based opinion statement by the EADV Task Force on Quality of Life. J Eur Acad Dermatol Venereol 31(3):424–431
doi: 10.1111/jdv.13985 pubmed: 27684717
Sampogna F, Abeni D, Gieler U, Tomas Aragones L, Lien L, Poot F et al (2020) Exploring the EQ-5D dimension of pain/discomfort in dermatology outpatients from a multicentre study in 13 European Countries. Acta Derm Venereol 100(8):adv00120
doi: 10.2340/00015555-3477 pubmed: 32250441
Sawant NS, Vanjari NA, Khopkar U, Adulkar S (2015) A study of depression and quality of life in patients of lichen planus. Sci World J 2015:817481
doi: 10.1155/2015/817481
AlOtaibi HM, AlFurayh NA, AlNooh BM, Aljomah NA, Alqahtani SM (2021) Quality of life assessment among patients suffering from different dermatological diseases. Saudi Med J 42(11):1195–1200
doi: 10.15537/smj.2021.42.11.20210560 pubmed: 34732551 pmcid: 9149728

Auteurs

Fangyi Xie (F)

Department of Dermatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.

Colleen M Morken (CM)

Department of Dermatology, Mayo Clinic Arizona, 5777 E. Mayo Blvd., Phoenix, AZ, 85054, USA.

Nan Zhang (N)

Department of Quantitative Health Sciences, Mayo Clinic Arizona, 5777 E. Mayo Blvd, Phoenix, AZ, 85054, USA.

Mark R Pittelkow (MR)

Department of Dermatology, Mayo Clinic Arizona, 5777 E. Mayo Blvd., Phoenix, AZ, 85054, USA.

Julio C Sartori Valinotti (JC)

Department of Dermatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.

Nneka I Comfere (NI)

Department of Dermatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.

Alexander Meves (A)

Department of Dermatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.

Dennis H Murphree (DH)

Department of Dermatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.
Department of Artificial Intelligence and Informatics, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.

Aaron R Mangold (AR)

Department of Dermatology, Mayo Clinic Arizona, 5777 E. Mayo Blvd., Phoenix, AZ, 85054, USA.

Julia S Lehman (JS)

Department of Dermatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. lehman.julia@mayo.edu.
Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. lehman.julia@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH